Please login to the form below

Medius Deal Watch table for March 2015

The top major pharma mergers, acquisitions and collaborations during the month were dominated by AbbVie's Pharmacyclics mega-merger

The highest value deals in March were again dominated by company acquisitions but only one mega merger, Abbvie's acquisition of Pharmacyclics.

The price of $21bn was regarded by many commentators as very high and there were accusations that Abbvie had overpaid - but the reason for this was not the share price premium. [Read the month's pharma deal commentary in full.]

Here Medius present a run down of the month's biggest mergers, acquisitions and collaborations from across the sector.

Licensor/Licensee Acquired / Acquirer	Deal type*	Product/Technology	Headline $m
Pharmacyclics / Abbvie	Company acquisition	Marketed BTK inhibitor for haematological cancers + pipeline incl. 3 products in clinic	21,000
Auspex / Teva	Company acquisition	Phase 3 product for Huntington's Chorea + deuterium technology platform	3,500
Ikaria / Mallinckrodt	Company acquisition	Marketed critical care treatments incl. respiratory for neonatals	2,300
Cordis (J&J) / Cardinal Health	Company acquisition	J&J divest subsidiary marketing vascular devices	1,944
Covis / Concordia	Asset acquisition	18 marketed brands and generics in US acquired by Canadian company	1,200
Hyperion / Horizon	Company acquisition	2 marketed urea cycle disorder orphan drugs in the US	1,100
Bavarian Nordic / BMS	Option to license and commercialise	Phase 3 immuno-oncology treatment for prostate cancer	975
Intrexon / Merck Serono	Licence and collaboration + option	CAR-T immuno-oncology platform for identifying and developing target molecules	941
AstraZeneca / Daiichi Sankyo	Co-commercialisation US	Marketed Movantik (naloxegol) for opioid induced constipation	825
Aduro / Novartis	Licence and collaboration	Preclinical cancer immunotherapies targeting the STING (Stimulator of Interferon Genes) pathway	750
Hanmi / Eli Lilly	Licence and collaboration**	Phase 1 BTK inhibitor for treatment of lupus	690
Innovent / Eli Lilly	Strategic alliance	Development and commercialisation with Chinese company 3 preclinical oncology drugs†	456+
Zogenix / Pernix	Acquisition product	US marketed hydrocodone (Zohydro ER) for treatment of pain	384
Cellular Dynamics / Fujiflim	Company acquisition	US-based developer and manufacturer of human cells	307
Blueprint / Alexion	Strategic collaboration China and rest of world	Kinase inhibitor platform for discovery of molecules for treatment of rare diseases	265
Immunogen / Takeda	Licence and collaboration + option	Antibody-drug conjugate (ADC) technology to develop 2 anticancer products + option on 3rd	230
SuppreMol / Baxter	Company acquisition	Biologic immuno-regulatory pipeline with phase 2 lead product for treatment of ITP and lupus	225
Athersys / Chugai	Licence and collaboration Japan	Phase 2 stem cell therapy for treatment of ischaemic stroke	205
Alkermes / Recro	Asset acquisition	Purchase of US factory and associated products and pipeline	170
Checkpoint Therapeutics / TG	Licence and collaboration	Human anti-PD-L1 and anti-GITR antibody preclinical programmes for haematological cancers	165
Brighthaven Ventures/ Islet Sciences	Licence and collaboration***	Phase 2b SGLT2 inhibitor remogliflozin for treatment of diabetes	117
Sorrento / Nantcell	Licence and collaboration	Discovery and development of anticancer products incl. CAR-T and checkpoint inhibitors PD-1 and PD-L1	110
Transtech / Calithera	Licence and collaboration	Portfolio of hexokinase II inhibitors for treatment of cancer	109
Astellas / Vical	Licence and collaboration	Preclinical antifungal ASP2397	100

* Licence and collaboration means exclusive global rights to develop and commercialise unless otherwise stated

** Global rights excluding China, Hong Kong, Taiwan and Korea

*** Global rights excluding Latin America, China, Korea, Taiwan and Japan

† Innovent to receive a total upfront payment of $56m and potential milestones of over $400m for one of the molecules, a preclinical immuno-oncology molecule.